Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C

Pires-Neto, Orlando de Souza; Amoras, Ednelza da Silva Graça; Queiroz, Maria Alice Freitas; Demachki, Sâmia; Conde, Simone Regina da Silva; Ishak, Ricardo; Cayres-Vallinoto, Izaura Maria Vieira; Vallinoto, Antônio Carlos Rosário

doi:10.1016/j.meegid.2020.104200

Cited by 16 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of in vitro experiments have indicated that HBV enhances the expression of the IL-6 and IL-1-β gene via transcriptional transactivation activity of hepatitis B virus X protein (HBx) and CRP (7). However, it has also been reported that decreased production of CRP in patients chronically infected with HCV decreased the level of CRP gene expression (8). Nonetheless, there is no systematic review of the relationship between HBV and HCV and CRP levels; thus, in the current meta-analysis, we tried to elucidate this relationship.…”

Section: Contextmentioning

confidence: 99%

CRP Levels in Viral Hepatitis: A Meta-Analysis Study

2020

View full text Add to dashboard Cite

Context: Viral hepatitis is a common infectious disorder with a high degree of mortality. The host immunological feedback to the hepatitis virus is dim and unable to down-regulate and clear infection. C-reactive protein (CRP), an acute phase reactant synthesized by hepatocytes in response to inflammatory reactions, facilitates apoptosis and phagocytosis. An effort has been made in the current meta-analysis study to elucidate the relationship between CRP and hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Methods: Eighteen published research articles on CRP levels of viral hepatitis patients were included in this study. A random-effects model was used to calculate the pooled mean level for CRP. Results: The pooled mean level of CRP hepatitis B and hepatitis C was 6.93 mg/L (95% CI: 3.04 - 10.81) and 2.31 mg/L (95% CI: 1.06 - 3.55), respectively. A high degree of variance was observed among the studies, with the I2 more than 90%. Conclusions: The pooled mean level of CRP was within the normal range in patients with hepatitis C; however, it was high in patients with hepatitis B. The pooled mean CRP level reported in this study can be useful to determine the level of liver damage in patients with viral hepatitis.

show abstract

Section: Contextmentioning

confidence: 99%

CRP Levels in Viral Hepatitis: A Meta-Analysis Study

2020

View full text Add to dashboard Cite

show abstract

“…CRP was already recommended as a predictive indicator for a variety of physical and mental illnesses, such as dengue fever, malaria, and viral infections [14][15]. Mild CRP rise, on the other hand, may or may not be significantly meaningful, based on the patient's status.…”

Section: C-reactive Proteinmentioning

confidence: 99%

“…In research conducted in the USA, CRP level was found to be a quick, easy, and cost-consuming technique for estimating the amount of tissue damage in COVID-19 individuals [14]. Furthermore, a Turkish study found that inflammatory markers including CRP, among others, were linked to illness intensity and might be utilized as a possible predisposing variable for COVID-19 advancement [19] The Severity of CRP and COVID-19…”

Section: Status Of Crp and Covid-19 Illness Progressionmentioning

confidence: 99%

C-reactive protein in patients with COVID-19

Muthanna

Ibrahim²,

Al-Awkally³

et al. 2022

ijhs

View full text Add to dashboard Cite

The coronavirus illness 2019 (COVID-19) has spread to over 200 countries and infected over 70 million individuals since December 2019. The precise nature of the SARS-CoV-2 infection is yet unknown. In this study, we look at whether a C-reactive protein biomarker can predict clinical outcome or is linked to the severity of COVID-19 illness. Potential research published from the COVID-19 pandemic to May 2022 was found using the databases MEDLINE, Hinari, Google Scholar, and Google search. To extract relevant facts from each original report, a format established in a Microsoft Excel spreadsheet was employed. The retrieved data were transferred to STATA/MP version 16.0 software for further analysis. Keywords such as "COVID-19," "SARS-CoV-2," and "C-reactive protein," among others, were searched to find relevant papers. Only studies that reported mean C-reactive protein levels and COVID-19 disease stage results were included. The review contained twenty papers. All investigations indicated that individuals with severe COVID-19 had considerably greater levels of C-reactive protein than patients with moderate illness. This review indicated that a specific biomarker may still be used to predict the risk of disease progression in asymptomatic and/or slightly too seriously unwell persons.

show abstract

“…Toll-like receptor (TLR) 4 activator, a typical PAMP with powerful biological functions, can regulate host inflammation, recruit granulocytes and macrophages to the infected sites and effectively promote pathogen clearance [16]. Furthermore, the insufficient activation of TLR4 signaling pathway in the host can promote the occurrence of infection and aggravate the progress of infection [1,17,18]. And it was found that the anti-infective capability was enhanced in clinical patients pre-treated with TLR4related immunoregulators [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Toll-like receptor 4 agonist-based nanoparticles orchestrate protection against sepsis

Zhao

Huang

et al. 2022

J Mater Sci

View full text Add to dashboard Cite

Sepsis, a life-threatening organ dysfunction induced by severe infection and uncontrolled host immune response, threatens the health of people all over the world. Herein, a type of nanoparticle formulation with simple components is synthesized by encapsulating monophosphoryl lipid A (MPLA), a TLR4 agonist, with poly(lactic-co-glycolic acid) (PLGA) nanoparticle. The obtained nanoparticles (MPLA@PLGA) could provide Escherichia coli (E. coli)-induced sepsis protection by regulating the immune system after sepsis challenge, including promoting the levels of various cytokines, boosting the percentage of natural killer cells and accelerating bacterial clearance. Notably, the survival mice pre-treated with these nanoparticles could resist repeated E. coli-induced sepsis. Our work therefore provides the great promise of MPLA@PLGA nanoparticles as a simple yet effective nano-drug for prevention and protection against E. coli-induced sepsis.

show abstract

Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C

Cited by 16 publications

References 19 publications

CRP Levels in Viral Hepatitis: A Meta-Analysis Study

CRP Levels in Viral Hepatitis: A Meta-Analysis Study

C-reactive protein in patients with COVID-19

Toll-like receptor 4 agonist-based nanoparticles orchestrate protection against sepsis

Contact Info

Product

Resources

About